Analysis of serum S100A12, sTREM-1, and S100A8/A9 for prognostic evaluation of myocardial injury in neonates with late-onset sepsis
Analyse von Serum-S100A12, sTREM-1 und S100A8/A9 zur prognostischen Bewertung einer Myokardschädigung bei Neugeborenen mit spät einsetzender Sepsis
Frontiers in Public Health · 10.11.2026 · 14
DOI: 10.3389/fpubh.2026.1907157 ↗Auf einen Blick
Bei 90 Neugeborenen mit spät einsetzender Sepsis und Myokardschädigung waren sTREM-1, S100A12 und S100A8/A9 bei Nichtüberlebenden höher als bei Überlebenden. Ein Kombinationsmodell zeigte eine moderate Prognoseleistung.
Fragestellung
Besteht bei Neugeborenen mit spät einsetzender sepsisbedingter Myokardschädigung ein Zusammenhang zwischen Serum-sTREM-1, S100A12 und S100A8/A9 und Prognose bzw. Mortalität?
Methode
Retrospektive Studie bei 90 Neugeborenen auf der NICU; Messung der Serumwerte innerhalb von 24 h nach Aufnahme; Follow-up über 28 Tage; Cox-Regression und Prognosemodell.
Ergebnisse
Nichtüberlebende hatten höhere Werte: sTREM-1 124,45 ± 13,13 vs. 108,72 ± 10,31 ng/mL; S100A12 19,91 ± 2,84 vs. 13,16 ± 2,43 ng/mL; S100A8/A9 1543,13 ± 157,05 vs. 1315,32 ± 100,01 ng/mL. AUCs: 0,724; 0,796; 0,779.
Einschränkungen
Prospektive multizentrische Validierung vor klinischer Anwendung erforderlich.
Schlussfolgerung der Autor:innen
Serum-sTREM-1 und S100A12 könnten zusätzliche prognostische Informationen liefern. Das Kombinationsmodell aus 3 Biomarkern zeigte eine moderate Vorhersageleistung.
Kernaussagen
- Nichtüberlebende hatten höhere sTREM-1-, S100A12- und S100A8/A9-Werte.
- sTREM-1 und S100A12 waren nach Adjustierung unabhängig mit Mortalität assoziiert.
- Das 3-Biomarker-Modell sagte 7-, 14- und 28-Tage-Mortalität moderat voraus.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 10.11.2026. Verfasst von Kai Yang und 7 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Objective
To investigate the association of serum sTREM-1, S100A12, and S100A8/A9 with prognosis and clinical outcomes in neonates with late-onset sepsis-induced myocardial injury. These biomarkers were selected because sTREM-1 is a soluble myeloid-cell–associated inflammatory receptor, whereas S100A12 and S100A8/A9 are inflammation-related S100 family proteins and damage-associated molecular patterns (DAMPs) that are involved in the amplification of inflammatory responses during sepsis. Their reported associations with infection severity and organ injury prompted us to investigate their potential prognostic value in neonatal sepsis-associated myocardial injury.
Methods
A total of 90 neonates diagnosed with late-onset sepsis-induced myocardial injury and admitted to the NICU of The First Affiliated Hospital of Zhengzhou University between May 2023 and November 2024 were retrospectively enrolled. Serum levels of sTREM-1, S100A12, and S100A8/A9 were measured within 24 h after admission. Patients were followed for 28 days after admission and divided into survival and non-survivor groups according to survival status. Cox regression analyses were performed to identify prognostic risk factors. A prediction model was constructed based on independent risk factors, and its predictive performance for 7-day, 14-day, and 28-day survival was evaluated.
Results
Serum sTREM-1 levels in the non-survivor group were significantly higher than those in the survival group (124.45 ± 13.13 vs. 108.72 ± 10.31 ng/mL, p < 0.05). Similarly, serum levels of S100A12 (19.91 ± 2.84 vs. 13.16 ± 2.43 ng/mL) and S100A8/A9 (1543.13 ± 157.05 vs. 1315.32 ± 100.01 ng/mL) were significantly elevated in the non-survivor group compared with the survival group ( p < 0.05). Based on optimal cutoff values, elevated levels of the three biomarkers were associated with increased mortality. Cox regression analyses demonstrated that sTREM-1 and S100A12 were independently associated with mortality after adjustment for disease severity, while the three biomarkers together showed moderate accuracy in predicting 7-day, 14-day, and 28-day mortality (AUCs: 0.724 for sTREM-1, 0.796 for S100A12, 0.779 for S100A8/A9).
Conclusion
Serum sTREM-1 and S100A12 levels may provide incremental prognostic information in neonates with late-onset sepsis-induced myocardial injury. The combined model based on these 3 biomarkers showed moderate predictive performance and requires prospective multicenter validation before clinical implementation.
Zitieren
APA
Yang, K., Wang, Z., Wang, B., Wang, Y., Liu, T., Wei, K., You, G., & Yuan, D. (2026). Analysis of serum S100A12, sTREM-1, and S100A8/A9 for prognostic evaluation of myocardial injury in neonates with late-onset sepsis. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1907157
Vancouver
Yang K, Wang Z, Wang B, Wang Y, Liu T, Wei K, et al. Analysis of serum S100A12, sTREM-1, and S100A8/A9 for prognostic evaluation of myocardial injury in neonates with late-onset sepsis. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1907157
BibTeX
@article{Yang2026,
author = {Yang, Kai and Wang, Zhe and Wang, Bingxian and Wang, Yaru and Liu, Tao and Wei, Kaiyan and You, Guohua and Yuan, Dahai},
title = {Analysis of serum S100A12, sTREM-1, and S100A8/A9 for prognostic evaluation of myocardial injury in neonates with late-onset sepsis},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1907157}
}
EUVIMED